Molecular and Cellular Mechanisms of Electronegative Lipoproteins in Cardiovascular Diseases

Biomedicines. 2020 Nov 29;8(12):550. doi: 10.3390/biomedicines8120550.

Abstract

Dysregulation of glucose and lipid metabolism increases plasma levels of lipoproteins and triglycerides, resulting in vascular endothelial damage. Remarkably, the oxidation of lipid and lipoprotein particles generates electronegative lipoproteins that mediate cellular deterioration of atherosclerosis. In this review, we examined the core of atherosclerotic plaque, which is enriched by byproducts of lipid metabolism and lipoproteins, such as oxidized low-density lipoproteins (oxLDL) and electronegative subfraction of LDL (LDL(-)). We also summarized the chemical properties, receptors, and molecular mechanisms of LDL(-). In combination with other well-known markers of inflammation, namely metabolic diseases, we concluded that LDL(-) can be used as a novel prognostic tool for these lipid disorders. In addition, through understanding the underlying pathophysiological molecular routes for endothelial dysfunction and inflammation, we may reassess current therapeutics and might gain a new direction to treat atherosclerotic cardiovascular diseases, mainly targeting LDL(-) clearance.

Keywords: L5 LDL; LDL(−); LOX-1; atherosclerosis; cardiovascular disease; dyslipidemia; electronegative LDL; endothelial dysfunction; lectin-like oxLDL receptor-1; oxLDL; oxidized LDL.

Publication types

  • Review